Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors not yet approved by the MHRA or EMA as of April 2025
Written by Dieter Auto-translatedView all reviews
COA, HPLC/MS, salt form, and batch document review is treated as search context, not as a protocol or outcome claim
However, because the control beverage elicited similar lipid-lowering effects in hypercholesterolemic participants, and due to the short study duration and small sample size, further research is needed to clarify yerba mates long-term efficacy, optimal dosing, and potential role in populations with chronic conditions such as type 2 diabetes, obesity, or advanced cardiovascular disease
US$ 24.77
US$ 20.55
US$ 27.96
US$ 28.12
US$ 21.79
US$ 21.75
